Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | PPARG | P37231 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | STS | P08842 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CTSV | O60911 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21166318 | 0.98 | ALOX15 (0.66) | ALOX15PPARGMAPTSTSCYP11B1 | |
| SCHEMBL3660146 | 0.98 | ALOX15 (0.66) | ALOX15PPARGMAPTSTSCYP11B1 | |
| SCHEMBL3657376 | 0.98 | ALOX15 (0.66) | ALOX15PPARGMAPTSTSCYP11B1 | |
| SCHEMBL16893235 | 0.98 | ALOX15 (0.66) | ALOX15PPARGMAPTSTSCYP11B1 | |
| SCHEMBL3654554 | 0.98 | ALOX15 (0.66) | ALOX15PPARGMAPTSTSCYP11B1 | |
| SCHEMBL28050777 | 0.98 | ALOX15 (0.66) | ALOX15PPARGMAPTSTSCYP11B1 | |
| SCHEMBL3660694 | 0.95 | PPARG (0.65) | ALOX15PPARGMAPTSTSCYP11B1 | |
| SCHEMBL30694898 | 0.89 | PPARG (0.69) | ALOX15PPARGSTSCYP11B1CYP11B2 | |
| SCHEMBL3715533 | 0.89 | PPARG (0.69) | ALOX15PPARGSTSCYP11B1CYP11B2 | |
| SCHEMBL28428768 | 0.88 | ALOX15 (0.58) | ALOX15PPARGMAPTSTSCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118043044-A | Allosteric ketene inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024097206-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097205-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097721-A1 | TARGETING ALLOSTERIC AND ORTHOSTERIC POCKETS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4347040-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF CANCER | Petra Pharma Corporation (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117769546-A | Allosteric ketene inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4333984-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334312-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117693506-A | Allosteric ketone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-1604647-B1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | CHISSO CORP (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060018867-A1 | Cosmetic composition and production thereof | ICHIMARU PHARCOS CO., LTD | 2006-01-26 | — | — | US | disclosed |
| EP-1604647-A1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | Ichimaru Pharcos Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6903227-B2 | Synthesis of 2-acyl substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040044225-A1 | Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives | MILLENNIUM PHARMACEUTICALS, INC. | 2004-03-04 | — | — | US | disclosed |
| US-20030233002-A1 | Synthesis of 2-Acyl substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2001092249-A2 | CHIRAL AND ACHIRAL SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND THEIR DERIVATIVES | COR THERAPEUTICS, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001092250-A2 | SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND INTERMEDIATES THEREOF | COR THERAPEUTICS, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030233002-A1 | Synthesis of 2-Acyl substituted chromanes and intermediates thereof | PLA2G7, PAFAH1B2, PAFAH1B3 | ALOX15 153/4885PPARG 802/4885MAPT 4803/4885 |
| US-20040044225-A1 | Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives | ACAT2, ACACA, COASY | ALOX15 1258/4885PPARG 856/4885MAPT 4727/4885 |
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | ALOX15 3135/4885PPARG 695/4885MAPT 3441/4885 |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | CUTA, COL14A1, PRKDC | ALOX15 3447/4885PPARG 1178/4885MAPT 648/4885 |
| US-20060018867-A1 | Cosmetic composition and production thereof | CUTA, PARG, TYR | ALOX15 670/4885PPARG 1824/4885MAPT 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.